COMPANY RESEARCHT25 is an oral octreotide acetate tablet. MED&SSE produces its shell and drug-containing core; FDA IND clearance was disclosed in 2026.
The announcement states that JJDC will invest; closing and the amount were not disclosed. A $20.4 million pre-Series C round was previously announced on 2023-09-28.
Profile review: 2026-11-04 · Fields retain their individual source dates. Undisclosed values are not zero; early or historical events do not establish the latest financing. Awards and acquisitions are distinguished from equity rounds.
Disease tags match recorded text mentions and require program-level verification.
T25 uses MED&SSE and the 3DμS®-OM system for maintenance treatment of acromegaly.
A collaboration with Janssen Pharmaceutica NV and an equity investment by JJDC were announced on 2026-10-09.
2026-04-01: Triastek receives FDA IND clearance for oral octreotide candidate T25
2026-10-09: Triastek partners with Johnson & Johnson on oral medicines and announces JJDC investment
| Program / service | Target / indication | Representative stage | Evidence & scope |
|---|---|---|---|
| T25 | Somatostatin receptors · Acromegaly | IND clearance | Results not disclosed |
Company-name matches are discovery leads; verify entity identity and transaction roles in the original source.
Triastek and its Shanghai subsidiary entered a collaboration and license agreement with Janssen Pharmaceutica NV to develop oral medicines using 3D printing and delivery technologies for peptides and other modalities. JJDC will also make an equity investment. Financial terms and named collaboration candidates were undisclosed, and the agreement does not establish clinical performance for T25.
Triastek announced FDA IND clearance for T25, a modified-release oral octreotide acetate tablet intended for maintenance treatment of adults with acromegaly who respond to somatostatin analogs. The candidate combines MED&SSE printing with its 3D microstructure delivery system. Clearance enables clinical development; the announcement did not provide human pharmacokinetic or efficacy results.
Johnson & Johnson reported that 58% of patients receiving icotrokinra 200 mg achieved ACR20 at Week 16 in ICONIC-PsA 1, versus 41% with placebo. The oral IL-23 receptor peptide also showed skin responses. The company reported no new safety signals through Week 24; active psoriatic arthritis remains an investigational indication.
Entera reported $265.9 million in cash and cash equivalents at September 30, plus $6.5 million in restricted cash. Its November 6 update targets first site activation for an approximately 900-patient EB613 osteoporosis Phase 3 trial in late 2026. EB613 is an oral PTH(1-34) program, included here as an adjacent oral-peptide delivery development, not a cyclic-peptide candidate.
Johnson & Johnson reported that ICONIC-ASCEND met its Week 16 co-primary endpoints: PASI 90 responses were 55.2% with icotrokinra versus 3.6% with placebo, and IGA 0/1 responses were 70.4% versus 9.5%. At Week 28, the oral peptide met noninferiority criteria versus ustekinumab across multiplicity-controlled key secondary skin-clearance endpoints.
Discussions are for signed-in members. Personal notes remain separate from company research.
Sign in to joinInclusion is not endorsement or partner qualification. Assess company claims, clinical evidence, and project-specific capabilities separately.